1. Home
  2. LEU vs ANAB Comparison

LEU vs ANAB Comparison

Compare LEU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centrus Energy Corp.

LEU

Centrus Energy Corp.

HOLD

Current Price

$248.98

Market Cap

4.2B

Sector

Industrials

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$48.03

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEU
ANAB
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
1.4B
IPO Year
1998
2017

Fundamental Metrics

Financial Performance
Metric
LEU
ANAB
Price
$248.98
$48.03
Analyst Decision
Buy
Buy
Analyst Count
12
11
Target Price
$243.00
$59.90
AVG Volume (30 Days)
875.0K
433.4K
Earning Date
02-05-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
31.25
N/A
EPS
6.17
N/A
Revenue
$454,100,000.00
$169,467,000.00
Revenue This Year
$1.17
$135.45
Revenue Next Year
$8.96
N/A
P/E Ratio
$40.40
N/A
Revenue Growth
15.25
196.42
52 Week Low
$49.40
$12.21
52 Week High
$464.25
$52.47

Technical Indicators

Market Signals
Indicator
LEU
ANAB
Relative Strength Index (RSI) 45.33 60.39
Support Level $244.38 $49.50
Resistance Level $263.73 $52.47
Average True Range (ATR) 19.48 2.34
MACD 2.29 -0.04
Stochastic Oscillator 47.05 47.01

Price Performance

Historical Comparison
LEU
ANAB

About LEU Centrus Energy Corp.

Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: